MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One ...
August 05 2019 - 9:00AM
MannKind Corporation (NASDAQ: MNKD) and One Drop
today announced that they have signed a collaborative agreement
that is intended to integrate MannKind’s BluHale® accessory device
into the One Drop platform. BluHale is a Bluetooth-connected
accessory that attaches to the Afrezza® inhaler and is
designed to convey real-time information about inhalation effort
and insulin dose. The goal of this collaboration is to
provide a seamless experience for Afrezza patients, including
automatic tracking of their insulin doses as well as other
important health information on the One Drop platform. The
agreement is expected to bring One Drop’s award winning user
experience to Afrezza users, empowering them with AI-enabled
glucose forecasts, predictive insights, and the opportunity to
connect one-on-one with One Drop’s certified diabetes educators, an
educational service that has been recognized by the American
Diabetes Association.
“Earlier this year, One Drop announced clinical
data that demonstrated using Afrezza with One Drop provided a
significant improvement in A1C levels. We now look forward to
integrating automatic dose detection into their platform in order
to further evolve the patient experience,” said Michael Castagna,
CEO of MannKind Corporation. “We believe the future of diabetes
management will increasingly depend on data collected on a
smartphone that provides real time decision support insights that
will help patients and providers achieve improved outcomes.”
“For too long, people with diabetes have been
trying to make decisions about what to do and when to do it by
looking in the rear-view mirror,” said Jeff Dachis, CEO of One
Drop. “Having automated dose detection with Afrezza will be a huge
step forward in helping to remove burden from people’s care
regimen, and will enable powerful, data-driven insights,
potentially leading to even better patient health outcomes.”
About Afrezza® Available by prescription,
Afrezza® (insulin human) Inhalation Powder is a rapid-acting
inhaled insulin indicated to improve glycemic control in adult
patients with diabetes mellitus. Afrezza consists of a dry
powder formulation of human insulin delivered from a small and
portable inhaler. Administered at the beginning of a meal, Afrezza
dissolves rapidly upon inhalation to the lung and passes quickly
into the bloodstream (in less than one minute). This rapid
absorption allows Afrezza to begin reducing blood sugar levels
within minutes of administration. Afrezza is available in
4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder
that can be used, as prescribed by a health care professional, in
combination with other diabetes medications to achieve target blood
sugar levels. For Afrezza doses exceeding 12 units, patients
may use a combination of existing cartridge strengths. For more
information about Afrezza, please visit www.afrezza.com.
About MannKind CorporationMannKind
Corporation (NASDAQ:MNKD) focuses on the development and
commercialization of inhaled therapeutic products for patients with
diseases such as diabetes and pulmonary arterial
hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company's
first FDA-approved product and the only orally inhaled ultra
rapid-acting mealtime insulin in the United States, where it
is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs
field sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
About One DropOne Drop is a digital health
company harnessing the power of mobile computing and data science
to transform the lives of people with diabetes worldwide. The One
Drop platform brings affordable, accessible diabetes care to
everyone with diabetes and a smartphone, as well as their
employers, insurers and health care providers. One Drop’s consumer
services are available for purchase in-app (iOS and Android) and
at getonedrop.com. One Drop | Mobile is available
for free download worldwide (iOS and Android). And, for
more information on helping your organization lower the cost of
care, contact results@onedrop.today.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve risks and
uncertainties. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based
upon MannKind's current expectations. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties detailed in MannKind's filings with
the SEC. For a discussion of these and other factors, please
refer to MannKind’s quarterly report on Form 10-Q for the quarter
ended March 31, 2019 as well as MannKind’s other filings
with the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement,
and MannKind undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date of this press release.
MannKind Contact:Rose
AlinayaInvestor Relations818-661-5000ir@mannkindcorp.com
One Drop Contact:Rachel Sanchez-Madhur
contact@onedrop.today
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2024 to Oct 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Oct 2023 to Oct 2024